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Summary Background Although DNA-directed alkylating
agents and related compounds have been a mainstay in che-
motherapeutic protocols due to their ability to readily interfere
with the rapid mitotic progression of malignant cells, their
clinical utility is limited by DNA repair mechanisms and im-
munosuppression. However, the same destructive nature of
alkylation can be reciprocated at the cell surface using novel
plasma membrane alkylating agents. Results Plasma mem-
brane alkylating agents have elicited long term survival in
mammalian models challenged with carcinomas, sarcomas,
and leukemias. Further, a specialized group of plasma mem-
brane alkylating agents known as tetra-O-acetate
haloacetamido carbohydrate analogs (Tet-OAHCs) potenti-
ates a substantial leukocyte influx at the administration and
primary tumor site, indicative of a potent immune response.
The effects of plasma membrane alkylating agents may be
further potentiated through the use of another novel class of
chemotherapeutic agents, known as dihydroxyacetone phos-
phate (DHAP) inhibitors, since many cancer types are known
to rely on the DHAP pathway for lipid synthesis. Conclusion
Despite these compelling data, preliminary clinical trials for
plasma membrane-directed agents have yet to be considered.
Therefore, this review is intended for academics and clinicians
to postulate a novel approach of chemotherapy; altering critical
malignant cell signaling at the plasma membrane surface
through alkylation, thereby inducing irreversible changes to
functions needed for cell survival.
Keywords Plasmamembrane .Alkylatingagents .Leukocyte
influx . Carbohydrate analogs . Dihydroxyacetone phosphate
inhibitors
Introduction
Alkylation of vital intracellular nucleophiles is a nonspecific,
but effective antineoplastic strategy in many hematological
malignancies and some solid tumors due to subsequent per-
turbation of cell proliferation. Ever since Goodman, Gilman,
and colleagues at Yale began investigating the potential of
nitrogen mustards in 1942, alkylating the DNA of rapidly
proliferating cells has been seen as a logical and highly effec-
tive method to mitigate neoplastic growth [1]. Such agents are
known for covalently modifying nitrogenous bases in DNA,
prompting the formation of adducts, and potentially crosslinks
in the case of difunctional agents that eventually induce apo-
ptotic signaling [2]. The success of alkylating agents has
prompted the development of pseudo-alkylating agents such
as cisplatin (cis-diamminedichloroplatinum(II)) and related
derivatives which induce 1,2-intrastrand crosslinks with pu-
rine bases, but have no alkyl groups available for an alkylation
reaction [3, 4].
As with other nonspecific cytotoxic antineoplastic agents,
alkylating agents and related compounds have notable limita-
tions. In addition to their less than ideal toxicity profile, the
crosslinking capability of these agents is considerably reduced
in the presence of the DNA-repair enzyme O-6-
methylguanine-DNA methyltransferase (MGMT) [2, 5, 6].
Alkylating-like agents also face a similar problem of rapid
DNA repair as the propensity of nucleotide excision repair
(NER) is ever-present in a substantial variety of cancers. This
is exemplified by non-small cell lung carcinomas (NSCLCs)
which have particularly dismal prognoses due to their ability
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to mitigate the effects of platinum-based agents, other tradi-
tional chemotherapeutic approaches, and biologics [7–10].
Therefore, the ability of malignant cells to repair damaged
DNA is an apparent constraint on the efficacy of currently
approved alkylating agents. If there was a way to reciprocate
the same destructive nature of alkylation in organelles besides
the nucleus, high rates of apoptosis, and other forms of cell
death may still be observed in the presence of DNA
alkylation-resistant cells.
Such a novel chemotherapeutic approach may be attained
by alkylating the plasma membrane of neoplastic cells. It has
been known for quite some time that plasma membrane pro-
teins exposed on the cell surface have important biological
functions, such as cell signaling, ion transport, and cell-cell
and cell-matrix adhesion interactions [11–14]. Due to recent
advances in genomic, transcriptomic, and proteomic analysis,
it has been elucidated that the expression level ofmany plasma
membrane proteins is altered in malignant cells [11, 12, 15].
Such protein alterations often confer metastatic properties,
creating a target for antibodies and other biologics used in
the clinical setting. While such agents target specific aber-
rancies on the cell surface, alkylating agents could react non-
specifically with functional groups on the exterior of the plas-
ma membrane [16], circumventing the need for a designated
target to be present.
Since cell surface glycoconjugates are pivotal in surface
membrane biochemistry, it is plausible that altering such sig-
naling through alkylation could have profound chemothera-
peutic activity. In fact, numerous in vitro and in vivo experi-
ments have demonstrated the potential efficacy of plasma
membrane alkylating agents that target carbohydrate moieties
[17–21]. This should come as no surprise as cell surface car-
bohydrates are involved in multitudes of important physiolog-
ical processes. Carbohydrates are involved in the adhesion of
cells to substrates, as well as their adherence to each other.
They have shown to change in accessibility as a function of
the cell cycle, and have been indicated to play a pivotal role in
cell differentiation [14, 15].
Further, cell surface carbohydrates have a profound in-
fluence on host immune response. Lectin-like carbohydrate
binding sites are integral for the interaction of cytokines
with their targets. Carbohydrates are also involved in the
chemotaxis and extravasation of granulocytes and mono-
nuclear agranulocytes, indicating that agents with a carbo-
hydrate moiety may influence host immunogenicity. The
humoral immune response is also markedly characterized
by carbohydrate dependence, as T-lymphocytes have
lectin-like carbohydrate receptors that affect antigen-
specific in vitro assays [17, 18].
Despite these data, preliminary clinical trials for
carbohydrate-mediated plasma membrane alkylating agents
have yet to be considered. Therefore, this review is intended
for academics and clinicians to postulate a novel approach to
chemotherapy; altering critical malignant cell signaling at the
plasma membrane surface through alkylation, thereby induc-
ing irreversible changes to functions needed for cell survival.
It is hoped that such an analysis will provide enough data to
warrant further in vivo and eventual clinical trials, ultimately
potentiating a new paradigm of chemotherapeutic agents.
In vivo data provide characteristics of ideal plasma
membrane alkylating agents
Many plasma membrane alkylating agents have been shown
to exert significant physiological effects by chemical alter-
ation of surface membrane electron donors, particularly at
carbohydrate-specific receptor sites due to a reactive α-halo
functional group, as well as their observed amphiphilic nature.
In particular, halocarbonyls (haloketones, haloesters, and
haloacetamides) have shown significant antitumor activity in
murine models after only a single injection of an active agent
[16–18]. However, simple haloacetamides and haloacetates
are not active against Ehrlich ascites murine carcinoma in
CD2F1 mice [17], suggesting that active halo compounds
have particular physicochemical properties atypical of com-
mon halo compounds.
Critical analysis of effective halo compounds in vivo
has revealed such agents are able to partition from an
aqueous to hydrophobic environment (amphiphilic log P
value), and have a marked propensity to act as SN2
alkylators that react with strong electron donors [21].
By contrast, related compounds that are only strong
alkylators, or amphiphilic do not potentiate the same
antitumor activity [16–18]. Further, active haloacetamide
compounds often have additional electron withdrawing
groups which greatly increase alkylation potential. The
pKa o f the pa r en t amine f rom which ac t i ve
haloacetamide compounds are made correlates well with
the alkylating activity of the antitumor agents, as is
expected; the more acidic the pKa, the more reactive
the derived α-haloacetamide should be. In fact, their
reactivity at the CH2X group is controlled by the elec-
tron withdrawing or donating power of the R-group, and
the corresponding pKa of the parent amine (Fig. 1a).
This also happens to be the case with nitrogen mustards
which have long been used in the clinical setting due to
their alkylating potential. However, haloacetamides have
apparent hydrogen bond donating and accepting proper-
ties due to the presence of the amide nitrogen, indicat-
ing that compounds can be designed to have their ac-
tivity modulated by the dielectric constant of the in vivo
environment [21]. That localization could in turn be
readily controlled by the lipid: water partition coefficient
of the given haloacetamide. Further, nitrogen mustards
react by SN1 mechanisms [22], which are not partial to
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hydrophobic environments; ideal for alkylating hydrophilic
DNA, but not the hydrophobic environment of the plasma
membrane. Due to the SN2 mechanisms observed in
haloacetamides, the compounds react with electron donors
even in nonpolar environments, allowing alkylation of func-
tional groups on the surface of the plasma membrane to be a
feasible prospect.
Further improving specificity using acetylated
carbohydrate derivatives
Experimental data comparing structural activity and chemo-
therapeutic effectiveness have confirmed that halo carbonyls
act as non-charged hydrophobic or amphiphilic electrophiles.
Further, the compounds with the most antitumor activity
in these series are strong alkylating agents. Since anti-
tumor activity is dependent on the polarity and
alkylating activity of halo carbonyls, it has been postu-
lated, and later confirmed that such analogs exert their
effects by alkylating cell surface nucleophiles. To fur-
ther improve the specificity of haloacetamides, the R
group has been substituted with carbohydrate derivatives
that are found on the plasma membrane. However,
inserting a hydrophilic moiety into the base structure
significantly reduces antitumor activity, as observed by
haloacetamides with free sugars [17, 18]. Therefore, any
carbohydrate structure inserted into the haloacetamide
C
Fig. 1 Characterization of haloacetamide structure. a General structure
of haloacetamides. The highly reactive halogen (X) is ideal for an
alkylation reaction. Such compounds are known to react by SN2
mechanisms, enabling a concerted reaction to occur in hydrophobic
environments, such as the plasma membrane. Reactivity at the CH2X
group is controlled by the electron withdrawing or donating power of
the R group, and the corresponding pKa of the parent amine. The
hydrogen bond donating and accepting properties of the amide nitrogen
allow the reactivity to be modulated by the dielectric constant of the
in vivo environment. b Basic structure of haloacetamido carbohydrates.
C) Synthesis of tetra-O-acetylated D-mannose analogs. A different set of
reactions are needed to make the fluoro derivative compared to the bromo
and chloro derivatives. Mannose analogs were devised since 2-deoxy-2-
acetamido-D-mannose is a metabolic precursor for sialic acid, a vital
component of cell-surface biochemistry. Panels A and B were adapted
from [21]. The scheme for D-mannose analogs was adapted from [18]
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base structure needs to be altered so that the resulting
compound retains its affinity for nonpolar environments.
One approach to circumvent this issue has been to acetylate
the carbohydrate derivatives with acetic anhydride after being
attached to the haloacetamide (Fig. 1b and c). From this ap-
proach, a comprehensive series of tetra-O-acetate haloacetamido
carbohydrate analogs (Tet-OAHCs) have been developed to
mimic carbohydrates used at the plasma membrane surface,
including 2-deoxy-2-acetamido-β-D-glucose and its α anomer,
2-deoxy-2-acetamido-β-D-galactose, and 2-deoxy-2-
acetamido-D-mannose. The mannose derivative is particularly
important, as it is a metabolic precursor of sialic acid, an integral
component of cell surface biochemistry [23–25]. In fact, meta-
static cancer cells often express a high density of sialic acid-rich
glycoproteins, creating a negative charge on cell membranes
[26, 27]. The subsequent repulsion between adjacent malignant
cells is pivotal for the metastasis of many late stage cancers,
providing an optimal target for haloacetamidomannose analogs.
The importance of the hexose tetra-O-acetate carbohydrate
moiety for haloacetamides has become apparent in the treat-
ment of tumor-bearing mice. Several compounds in the glu-
cosamine, galactosamine, and mannosamine series have pro-
duced considerable rates of long term survival with almost all
mice surviving an intraperitoneal (i.p.) injection of 2.5×107
Ehrlich ascites carcinoma cells, a concentration that is ten
times the minimum dose lethal to 95 % of B6D2F1 mice
[21]. By contrast, simple haloacetamide and haloacetyl com-
pounds were completely inactive in the tumor-bearing mam-
malian system [21]. Further, non-hexose bromoacetamido
polyol acetates with alkylating activities and log P values
spanning those of the active bromoacetamido hexose tetra-
O-acetates did not exhibit antitumor activity [21]. Therefore,
the chemotherapeutic potential of Tet-OAHCs requires more
than the physicochemical properties of alkylating activity and
the octanol: water partition coefficient, as it is associated with
the specific interaction these agents can confer with functional
groups on the surface of the plasma membrane.
Tetra-O-acetylated haloacetamido carbohydrate
analogs potentiate leukocyte influx
It is has been well-established that carbohydrates are pivotal
for leukocyte function. O-linked glycans of glycosylation-
dependent cell adhesion molecule-1 (GLYCAM-1) are used
by leukocytes to home in on sites of inflammation, as well as
direct lymphocytes to lymph nodes [28]. Further, carbohy-
drates are critical for diapedesis, an innate form of extravasa-
tion in which carbohydrate ligands on the circulating leuko-
cytes bind selectin molecules on the inner wall of the vessel,
enabling the blood cells to slow down and begin rolling along
the inner surface of the vessel wall until they have passed
through the vascularized tissue [29, 30]. Therefore, it seems
plausible that carbohydrate-based chemotherapeutic agents
could have a profound influence on leukocyte influx at the
site of administration.
When N-bromoacetyl-β-D-glucosamine tetra-O-acetate
(NBrAcGlc-TA) was shown to produce consistent long term
remission in Ehrlich tumor-bearing mice after a single injec-
tion (0.11 mmol/kg), it was observed that the sites of tumor
challenge and drug administration had a rapid granulocyte
influx [21]. Further, N-bromoacetyl-β-D-galactosamine
tetra-O-acetate (NBrAcGal-TA) injected i.p. at the same
dose one day prior to a challenge of 1×106 Ehrlich ascites
carcinoma cells conferred substantial resistance to lethal
tumor outgrowth when compared to vehicle-treated control
animals . Al though plasma membrane alkylat ing
chlorohydroxyacetone-benzoate derivatives were shown to
produce long term survival in the same tumor system [31],
they were not associated with an increased granulocyte influx,
nor did pretreatment of such compounds one day prior to
tumor challenge confer any noticeable resistance.
To further examine whether Tet-OAHCs potentiate a sub-
stantial in vivo immune response, NBrAcGlc-TA and
chlorohydroxyacetone dinitrobenzoate (ClHA-DNB) were
injected at their respective effective doses in B6D2F1 mice
in the absence of tumor challenge [31]. Results from the study
indicated that only the carbohydrate analog produced a
marked early increase in granulocyte influx, as well as a
pronounced increase in later lymphocyte response. A
quantitative comparison of host leukocyte influx between car-
bohydrate analogs and another hydrophobic monofunctional
non-carbohydrate alkylating agent, bromohydroxyacetone
benzoate (BrHAB), later confirmed the in vivo observa-
tions [21]. It is worth noting that a difunctional alkylating
nitrogen mustard was not able to confer any protection to
tumor challenge when administered prior to the injection,
and significantly reduced host resistance against Ehrlich
ascites carcinoma due to its pronounced immunosuppressive
effects [21].
Efficacy in other cancer models
Although most studies investigating the chemotherapeutic ef-
ficacy of plasma membrane alkylating agents have been done
with Ehrlich ascites carcinoma, the compounds have shown
promise in other cancer models as well. In particular,
chlorohydroxyacetone esters were shown to produce long
term survival in mice challenged with murine sarcoma 180
and P815 murine mastocytoma [31]. However, plasma
membrane alkylating agents have demonstrated substantial
efficacy in disseminated hematological malignancies as well.
Tet-OAHCs were first examined in vitro against Friend
murine erythroleukemia cells [17]. Results from the study
indicated that the malignant cells in log phase suspension
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culture were substantially inhibited by low concentrations of
bromoacetamido and chloroacetamido analogs of the glucose
and galactose series.
The success of plasma membrane alkylating agents against
Friend erythroleukemia in vitro prompted an in vivo study
examining the effects of such compounds on the immunoge-
nicity of the malignant cells. When DBA/2 J mice treated with
chlorohydroxyacetone benzoate (ClHAB) survived a primary
challenge of a single injection of 1×106 tumorigenic cells, the
survivors were completely resistant to rechallenge. By con-
trast, a single injection of sonically disrupted Friend
erythroleukemia cells or of virus harvested from cultured cells
had no effect on the survival time of animals subsequently
rechallenged with intact cells, indicating that ClHAB potenti-
ates an immunogenic response. Further, mice given injections
of cells killed by exposure to 50 μMClHAB in vitro exhibited
increased survival times upon rechallenge. It was later dem-
onstrated that Friend erythroleukemia cells treated for 3 h with
30 μM ClHAB were non-proliferative in subculture, and
completely non-tumorigenic when implanted either i.p. or
subcutaneously (s.c.) into DBA/2 J hosts. In fact, mice receiv-
ing a single injection of 1×106 cells altered under these con-
ditions were fully protected against rechallenge. These results
are indicative of substantial reductions in tumorigenicity, as it
is known that as few as 10 cells of Friend erythroleukemia are
needed to kill murine models [32, 33]. Therefore, controlled
modification of Friend erythroleukemia cells by exposure to
relatively low concentrations of ClHAB abrogated the tumor-
igenicity of treated cells, without altering their ability to confer
protection to subsequent rechallenge with unaltered cells.
Potentiating activity by exploiting differences
in phospholipid metabolism
Although carbohydrate analogs offer a potentially specified ap-
proach to alkylate functional groups vital for neoplastic cell
stability, it is likely that some cells within various cancer types
will have inherent or acquired resistance to the series of com-
pounds. Therefore, finding additional agents that can supple-
ment the mechanisms of plasma membrane alkylating agents is
clinically relevant, as it will give clinicians a greater diversity of
options in which to treat problematic tumorigenic growths.
NAD-linked glycerol-3-phosphate dehydrogenase
(GPDH) is a key enzyme linking carbohydrate metabolism
with the synthesis and degradation of glycerolipids, yet it is
present in low amounts or entirely absent in most neoplastic
tissues [34–36]. Since phospholipids are required for the syn-
thesis of new membranes in proliferating cells, absence of this
enzyme in malignant cells is profound, and indicates that al-
ternative pathways to glycerolipids are pivotal for the poten-
tiation of neoplastic tissue. Such an alternative pathway exists
in which dihydroxyacetone phosphate (DHAP) is acylated
and reduced to lysophosphatidic acid by a microsomal
NADP-linked enzyme entirely independent of cytosolic
GPDH [37–40]. The acyl-DHAP pathway results in phospho-
lipid synthesis, as well as production of ether lipids that are
often elevated in various cancer types, indicating that such
compounds influence the abnormal growth patterns of these
malignancies [35]. Therefore, DHAP analogs designed to ex-
ploit the aberrant activity of GPDH could profoundly interfere
with lipid metabolism and membrane glycerol-lipid synthesis,
making affected cells much more sensitive to chemotherapeu-
tic agents that directly attack the plasma membrane.
Attempts have been made to exploit these potential differ-
ences and to alter membrane-mediated phenomena in neoplas-
tic tissue directly at the level of membrane lipids, as well as
indirectly by affecting lipid metabolic pathways. Success has
been achieved with halo analogs of GPDH and DHAP
[41–43] which are designed to exploit the differences in
GPDH production between malignant and normal cells. The
glycerol analogs directly exploit the difference in GPDH,
while the DHAP analogs influence the GPDH and acyl-
DHAP pathways. These analogs have shown some in vivo
antitumor activity, but they experience difficulties traversing
the plasma membrane, as they are charged, phosphorylated
compounds [44]. Therefore, non-phosphorylated derivatives
of dihydroxyacetonemay be pivotal for increasing chemother-
apeutic activity. This reasoning is in alignment with previous
observations that monobenzoate esters of dihydroxyacetone
inhibit the acyl-DHAP pathway. However, the inhibitory ef-
fect of monobenzoate esters is substantially limited in vivo by
endogenous kinase activity which phosphorylates at the 1′
position of the compounds, resulting in the formation of 1,
3-DHA-monobenzoate, a non-inhibitory derivative [45].
Since non-phosphorylated halo derivatives of dihydroxyace-
tone are not susceptible to kinase inactivation, they could be
used as potent inhibitors of the acyl-DHAP pathway.
Novel compounds worth investigating
for chemotherapeutic potential
Although a considerably diverse set of plasma membrane
alkylating agents have been examined for chemotherapeu-
tic potential, they are only preliminary investigations in
what could turn out to be a large class of similarly de-
signed chemotherapeutic agents. Plasma membrane
alkylating agents are only in their initial stages of devel-
opment, and many more compounds can be designed and
studied for anticancer activity. For example, it has been
observed that haloacetamide compounds that exhibit
alkylating potential have their reaction rate dictated by
hydrogen bonding [17]. While hydrogen bond accepting
by C=O, C-O, and C-N structures accelerate the rate of
alkylation, hydrogen bond donation by N-H decreases
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observed activity. It would therefore seem apparent that
agents without a hydrogen on the amide nitrogen could
be particularly effective alkylators. Further, since hydrogen
bonding can be exploited as a means to enhance alkyl-
ation in a hydrophobic environment, compounds should be
designed to examine potential therapeutic benefits con-
ferred from such activity. Pragmatic requirements to ob-
serve hydrogen bond controlled enhancement of alkylation
by haloacetamides in low polarity medium are as follows:
1) Hydrogen bond donation by N-H is an effective gain of
an electron by N, indicating that the alkylation rate should
decrease; 2) Hydrogen bond acceptance by N-H or C=O
is an effective withdrawal of an electron, inherent for ac-
celeration of the alkylation rate; 3) Intramolecular hydro-
gen bonds forming 5 and 6-membered rings (including the
shared hydrogen) would be highly favored due to the
stabilization of ring formation; 4) Formation of ring
forming intramolecular hydrogen bonding would be fa-
vored in a medium of a low dielectric constant (such as
the plasma membrane) compared to a polar medium; 5)
Multiple intramolecular hydrogen bonds would be more
effective than solvent donated hydrogen bonding in en-
hancing alkylation rate; 6) Any intramolecular hydrogen
bonding should significantly enhance the rate of alkyl-
ation. Due the potential importance intramolecular hydro-
gen bonding could have in increasing plasma membrane
alkylating activity, several novel compounds have been
posited for chemotherapeutic investigation (Fig. 2a and b).
One of the most profound characteristics of plasma
membrane alkylating haloacetamides is their ability to po-
tentiate a substantial granulocyte influx at the drug admin-
istration and primary tumor site when attached to a tetra-
O-acetylated carbohydrate. Not only does administration of
such compounds 24 h after tumor challenge result in par-
ticularly high cure rates and resistance to rechallenges, but
pretreating mice with the congeners effectively prevents
tumor formation. Although consistent alkylation of the
plasma membrane is enough to warrant further investiga-
tion due to the importance of cell surface biochemistry in
neoplastic growth, the ability to potentiate an immune re-
sponse at the primary tumor site has notable clinical im-
plications, and further substantiates the utility of acetylated
carbohydrate haloacetamide analogs. It is apparent that
these compounds could have immediate therapeutic poten-
tial, and novel congeners have been proposed to further
examine this intriguing in vivo response (Fig. 2c and d).
The compounds utilize analogs of carbohydrates typically
observed on the cell surface to promote alkylating speci-
ficity. In addition to monofunctional carbohydrate deriva-
tives, difunctional haloacetamide compounds are also pos-
ited as a means to further increase alkylation rates. It is
also well known that difunctional alkylating agents have
the propensity to crosslink adjacent nucleophiles [1], and
in theory should give haloacetamido analogs another
mechanism by which to damage neoplastic cells.
Potential synergy with anthracyclines
Although this review has commented on novel plasma
membrane-directed agents, there is a class of clinically approved
antineoplastic agents that has a marked influence at the cell
surface. Anthracyclines are most commonly known as nucleic
acid-directed agents, as the compounds intercalate base pairs,
produce free radicals, and are potent inhibitors of DNA topo-
isomerase II [4]. However, it has also been well established that
anthracyclines (particularly doxorubicin) alter the fluidity of neo-
plastic cell plasma membranes [46, 47], and bind phospholipids
with considerably affinity [48, 49]. Some studies have also
indicated that extracellular doxorubicin is important for antican-
cer activity and that the compound demonstrates marked
cytotoxicity without entering the cell [4, 50].
While the combination of anthracyclines and plasma mem-
brane alkylating agents has yet to be assessed for drug syner-
gy, this concomitant chemotherapeutic approach is an intrigu-
ing possibility that would give these novel agents more versa-
tility if they ever reached the clinical setting. Indeed,
anthracyclines and DNA-directed alkylating agents are often
used in combination, with synergy being attributed to the pro-
duction of free radicals and alkylated adducts. Interestingly, it
has been demonstrated that doxorubicin produces free radi-
cals, including highly reactive hydroxyl species, at the cell
surface. Therefore, it is possible that the same synergy be-
tween anthracyclines and DNA-directed alkylating agents
may be reciprocated with plasmamembrane alkylating agents,
due to the combined effect of unstable free radicals and
alkylated adducts. However the potential cardiotoxicity of
plasma membrane directed agents has also yet to be assessed,
and would likely decide whether these agents could be used
concomitantly with anthracyclines, unless dexrazoxane or
other cardiotoxic reducing agents mitigate any substantial
aberrant drug interaction.
Conclusion
Plasma membrane alkylating agents are a novel class of anti-
neoplastic agents that have the potential to supplement current
chemotherapeutic protocols. Unlike traditional alkylating
agents, compounds that have an affinity for the cell surface
do not need to gain entry into the cellular interior, and there-
fore circumvent drug efflux mechanism of various cancer
types. In effect, such compounds offer a novel target for cli-
nicians to exploit in combinatorial chemotherapy that could be
used concurrently with DNA-directed alkylating agents, as
well as drugs of other mechanisms. Tet-OAHCs are
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particularly interesting carbohydrate-based alkylating agents,
as they potentiate a substantial granulocyte influx at the ad-
ministration and primary tumor site in addition to having high
alkylating activity in amphiphilic environments that together
potentiate sustained tumor regression in mammalian models
of malignancy (Fig. 3). This is a particularly important
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observation, as traditional DNA-directed alkylating agents of-
ten have aberrant side effects on the patient’s immune re-
sponse [4, 51, 52]. An antineoplastic agent that promotes leu-
kocyte influx could be a particularly beneficial supplement to
many current chemotherapeutic protocols, and warrants fur-
ther examination of these novel congeners.
However, there will inevitably be some neoplastic cells
resistant to the initial effects of plasma membrane alkylating
agents, which is why indirectly targeting the plasma mem-
brane of malignant cells through the use of halo and
nonphosphorylated analogs of DHAP in concurrence with cell
surface alkylation appears to be a sensible prospect. Unlike
normal cells, malignant cells often rely on the acyl-DHAP
pathway, as they have significantly depleted levels of GPDH.
Antineoplastic analogs of DHAP cripple the acyl-DHAP path-
way, leaving neoplastic cells very few options for lipid syn-
thesis. With an aberrant plasma membrane already present,
further perturbation with cell surface-directed alkylating
agents should potently inhibit many cancer types.
Although the plasma membrane is a relatively new thera-
peutic target, it may prove to be an effective method of acquir-
ing preferential damage through the introduction of novel an-
tineoplastic agents such as plasma membrane alkylators and
acyl-DHAP inhibitors. Since these compounds offer relatively
novel mechanisms of action, more in vivo studies, followed
by numerous clinical trials will be needed to accurately assess
whether plasma membrane-directed agents actually have ther-
apeutic efficacy. If plasma membrane alkylating agents and
DHAP analogs do prove to have clinical relevance, they could
be used concomitantly with currently approved chemothera-
peutic approaches to increase the efficacy of such protocols.
Needless to say, this will only occur through further in vivo
observation. Only through such measures will enough data be
acquired to definitively determine whether plasmamembrane-
directed agents have significant clinical relevance.
Fig. 2 Proposed compounds to enhance alkylation activity through
intramolecular hydrogen bonding and novel acetylated carbohydrate
analogs for preclinical evaluation. a Compounds that form a hydrogen
bond from acceptance by an amide nitrogen. b Compounds that confer
the same potential through hydrogen bond acceptance by a carboxamide
oxygen. Formation of ring forming intramolecular hydrogen bonding is
highly favorable in a medium of a low dielectric constant, typically
observed in low polarity environments. c Monofunctional derivatives
are as follows: I) N-bromoacetyl-galactosylamine-2,3,4,6-tetra-O-
acetate, II) 1-O-bromoacetyl-glucose-2,3,4,6-tetra-O-acetate, III) N-
bromoacetyl-fucosylamine-2,3,4-tri-O-acetate, and IV) 6-deoxy-N-
bromoacetyl-galactosamine-1,3,4-tri-O-acetate. D) Difunctional
derivatives are as follows: V) 1,2-di-O-bromoacetyl-β-D-galactose-
3,4,6-tri-O-acetate, VI) 1,6-di-O-bromoacetyl-α or β-D-galactose-2,3,4-
tri-O-acetate, VII) 2,6-di-N-bromoacetyl-2,6-dideoxy-2,6-diamino-
galactose-1,3,4-tri-O-acetate, and VIII) 2,6-di-N-bromoacetyl-2,6-
dideoxy-2,6-diamino-β-D-glucose-1,3,4-tri-O-acetate
Alkylate proteins bound to the plasma 
membrane, perturbing cell surface 
biochemistry.
Tet-OAHCs
Produce high rates of long term remission 
in Ehrlich ascites tumor-bearing mice.
Potenate host leukocyte inﬂux at the 
site of the tumor.




















Fig. 3 Antineoplastic mechanisms of tetra-O-acetate haloacetamido carbohydrate analogs
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